Emerald Mutual Fund Advisers Trust Has $4.66 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Emerald Mutual Fund Advisers Trust decreased its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 549,688 shares of the specialty pharmaceutical company's stock after selling 101,292 shares during the quarter. Emerald Mutual Fund Advisers Trust owned approximately 1.11% of KalVista Pharmaceuticals worth $4,656,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Aquatic Capital Management LLC bought a new stake in KalVista Pharmaceuticals during the fourth quarter valued at about $44,000. Tower Research Capital LLC TRC grew its holdings in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc increased its position in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 1,494 shares during the period. Martin Worley Group bought a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. increased its position in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after acquiring an additional 2,043 shares during the period.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 5,104 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the sale, the chief executive officer now directly owns 278,855 shares in the company, valued at approximately $2,738,356.10. This trade represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Venrock Healthcare Capital Par purchased 100,000 shares of the firm's stock in a transaction dated Wednesday, February 12th. The stock was purchased at an average cost of $9.23 per share, with a total value of $923,000.00. Following the acquisition, the insider now directly owns 5,217,285 shares in the company, valued at $48,155,540.55. This trade represents a 1.95 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 217,348 shares of company stock worth $2,014,773 and have sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Stock Down 0.4 %

Shares of KalVista Pharmaceuticals stock traded down $0.05 during trading on Friday, reaching $13.55. 520,715 shares of the company were exchanged, compared to its average volume of 409,172. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The business has a 50-day moving average price of $11.85 and a 200-day moving average price of $10.42. The firm has a market capitalization of $673.65 million, a price-to-earnings ratio of -3.72 and a beta of 0.39.

Analysts Set New Price Targets

A number of analysts have commented on KALV shares. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Jones Trading reissued a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. Finally, TD Cowen began coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).